The Role of Everolimus in Renal Cell Carcinoma

Everolimus (RAD001) is an orally administered agent that inhibits the mammalian target of rapamycin serine-threonine kinase. A phase III pivotal trial on everolimus, published in 2008, provided the first evidence for the efficacy of sequential therapy for patients with metastatic clear cell renal ce...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Kidney Cancer VHL
Autors principals: Meskawi, Malek, Valdivieso, Roger, Dell’Oglio, Paolo, Trudeau, Vincent, Larcher, Alessandro, Karakiewicz, Pierre I.
Format: Artigo
Idioma:Inglês
Publicat: Codon Publications 2015
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5345521/
https://ncbi.nlm.nih.gov/pubmed/28326273
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15586/jkcvhl.2015.43
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars